comparemela.com
Home
Live Updates
Short Primary Endpoint - Breaking News
Pages:
Short Primary Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Rationale for Shorter Endpoints in Biosimilar Clinical Trials
Rishi P. Singh, MD; and Michael A. Klufas, MD, comment on the reasoning behind a shorter primary end point for biosimilar studies.
Michaela klufas
Wet amd
Age related macular edema
Short primary endpoint
Anti vegf
vimarsana © 2020. All Rights Reserved.